Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU
Shots:
- Curium to get exclusive license to develop and commercialize PyL in EU and Progenics to get royalties on the net sales
- The focus of the agreement is to advance the P-III CONDOR study and further commercialize it in the US
- PyL is PSMA -targeted Positron Emission Topography (PET) used for visualizing bone & soft tissue metastases for determining metastatic prostate cancer. In Q1’ 19 Curium to get regulatory approval for PyL
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
